BALAXI PHARMACEUTICALS LIMITED — Board Meeting, 05-11-2024: Outcome of Board Meeting

Balaxi Pharmaceuticals’ Board approved unaudited financial results for Q2 FY24, reporting revenues of ₹220.47 crore and a net profit of ₹16.61 crore. The Company announced the resignation of Company Secretary and Compliance Officer Mr. Mahesh Inani, effective immediately, and appointed Mr. Mohith Kumar Khandelwal to the role, effective November 6, 2024. Detailed financial statements and audit reports are available on the company website.